中文

拓新药业 Revenue Breakdown

Period 2026-03-31 ・ Reported 2026-04-28
ItemAmountY/Y
Revenue¥0.09B-4.6%
Gross profit¥0.02B
Operating income¥-0.01B
Net income¥-0.01B
Gross margin24.4%Net margin -11.4%
Revenue Q/Q-13.4%

Revenue Segments

The filing did not disclose a revenue breakdown for this period.

Costs & Expenses

ItemAmount% of revenue
Cost of revenue¥0.07B75.6%
R&D¥0.01B10.2%
SG&A¥0.02B23.6%
Tax & other¥-0.00B-3.2%
Generate the full Sankey chart →

The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.

Other companies

华润材料深城交争光股份华兰股份广立微百诚医药天益医疗金埔园林雅创电子风光股份明月镜片兆讯传媒

Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies